By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
BusinessTechnology

Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.

The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.

Recent studies have indicated that the time to gain approval is dramatically different between a CE Mark in Europe and a 510K in the United States. The time it takes to get a product to market takes on average, 6 months in Europe, compared to 2 years in the US, but, there is no evidence that suggests products in Europe are not safe. Increasingly, companies are launching in Europe while waiting for approval in the United States. A special morning panel at OneMedForum NY 2011 will explore the merits of this strategy in terms of creating capital efficiency. It will consider other strategic planning considerations in the process of getting approval and reimbursement.

The morning session will explore the implications of this for emerging companies and investors and will focus on a case study of how to get approval,  considering both Europe  and the United States.

More Read

Prescription Drug Hijacking on the Increase
Preparing for a HIPAA Audit and Avoiding Disaster [INFOGRAPHIC]
The Currency of Social Media in HealthCare
Q & A Part One: Technology and Healthcare Efficiency—Not Always the Perfect Match
Why Do Hospitals Slow Down on Weekends?

Panelists include: Rod Barnes, former VP Reimbursement at Alcon Lab;  Rosina Robinson, RN, MEd, RAC, MDCI; Richard Naples, Sr. Vice President, Regulatory Affairs, Becton Dickinson; and Corinne Lebourgeois, Med C Partners .

Corinne Lebourgeois notes that reimbursement in Europe is very fragmented with healthcare and funding varying from country to country. She aims to dissect this issue and bring knowledge of navigating the  reimbursement process to the forefront.  While Europe is and will remain for the coming decade at least, the second-largest market for medical devices worldwide, with approximately 33 percent of global sales taking place there, it’s complexity is high. Although the European Union tries to harmonize its different regulatory systems, in practice many differences still exist in the application of reimbursement systems. These include a number of institutions involved in the whole process in a given country, the application time, and the number of product classes defined.

In today’s environment, payers are increasingly sophisticated and rely more and more upon specific clinical evidence and health economic data to drive the reimbursement process. This makes it necessary for regulatory professionals to involve reimbursement professionals early in the product planning process and adjust clinical and regulatory strategies— not only to meet FDA’s needs, but to also ensure that the product will be reimbursed adequately, achieving marketplace success.

Rosina  Robinson of MDCI is expected to comment on how regulatory strategies have changed over the last 5 years. In Europe, a 2007 Medical Device Directive reinforces the need of clinical data, yet even with that amendment that took effect last year, it has been a less difficult route to approval and reimbursement compared the  510 k process in the United States.

Rod Barnes has been performing global studies involving pharmaceuticals and medical devices for the last 13 years and will discuss his experience with devices getting reimbursement in the US faster than in Europe, a rarity.

The panel will meet Thursday June 23rd at the historical Roosevelt Hotel. For more information, click here.

 

TAGGED:healthcare businessmedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

Online Health Intervention Programs – Dealing With Attrition

June 2, 2011

Healthcare Data Security: How Bad is it?

June 25, 2011
BusinesseHealthMarketing

When Negative Reviews are Addressed Patient Satisfaction Can Double

May 6, 2019

A Framework for Embracing Cloud in Health and Healthcare

January 29, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?